Despite a downturn in M&A activity during the latter part of 2016, prospects are on the rise. In this article, we analyse what deals are on the table, coming to the table and those that are still in the kitchen waiting to be plated up!
Narasimharaju SN, senior manager — regulatory affairs and Mac Kella, senior regulatory affairs executive at ELC Group assess whether biosimilars are really interchangeable in the EU.
How do managers in the pharmaceutical industry ensure that their plant performs reliably and safely? Michael Dixey and Pete Hibbs of GGR Associates explain some of the reasons for poor performance and suggest how these problems may be overcome.
‘Last mile’ transportation and subsequent user storage conditions present unique challenges when it comes to ensuring the safe and effective use of pharmaceutical products.
The potential benefits of genomics are well documented in healthcare, European Pharmaceutical Manufacturer reporter Reece Armstrong examines the latest developments in the field.
Global provider of auto-ID solutions, SATO, has published a white paper looking at the role of traceability in a digital world and its role in competitiveness.
Thanks to ongoing research and development in pharmaceuticals, the sector is benefitting from ongoing innovation which is helping break new boundaries in healthcare. Lu Rahman explains.
An expensive cholesterol drug, evolocumab, which is prescribed on the NHS, is claimed to do nothing to prevent fatal heart attacks and strokes and a coalition of doctors have called for it to be withdrawn from use.
